ERBB2 and cancer: These CSCs interact with immunosuppressive immune cells thereby constructing immune‐suppressive niche, and inflammatory cancer‐associated fibroblast (iCAFs) to enhance stemness through upregulation of SOX9 and OLFM4, promoting drug resistance and proliferation via the AREG‐ERBB2 signaling pathway.